Shandong Xinhua Pharmaceutical has obtained the registration certificate for concentrated solutions of sodium, potassium, magnesium, and calcium for injections.
Xinhua Pharmaceutical (000756.SZ) announced that the company has received the "Drug Registration Certificate" for the concentrated solution of sodium, potassium, magnesium, and calcium for injection approved and issued by the National Medical Products Administration. This product is used for electrolyte supplementation when infusing solutions containing concentrated glucose or amino acids through central venous infusion, to maintain electrolyte dynamic balance in adult patients.
Shandong Xinhua Pharmaceutical (000756.SZ) announced that the company has received the "Drug Registration Certificate" for the concentrated solution of sodium-potassium-magnesium-calcium injection approved and issued by the National Medical Products Administration. This product is used for electrolyte supplementation when administering solutions containing concentrated glucose or amino acids through central venous infusion to maintain electrolyte dynamic balance in adult patients.
Related Articles

New Stock News | Yundong Intelligent Plans Hong Kong IPO CSRC Requires Supplemental Explanation of the Reasonableness of the Shareholder's Investment Price in the Last 12 Months.

New Stock News | Xingchen Tianhe plans to list on the Hong Kong Stock Exchange, and the China Securities Regulatory Commission requires clarification on the specific details of the business involving large-scale AI models.

New stock news: Shanghai Jingzhi plans to go public in Hong Kong. The China Securities Regulatory Commission requires an explanation of the related stock option incentive plan and relevant circumstances.
New Stock News | Yundong Intelligent Plans Hong Kong IPO CSRC Requires Supplemental Explanation of the Reasonableness of the Shareholder's Investment Price in the Last 12 Months.

New Stock News | Xingchen Tianhe plans to list on the Hong Kong Stock Exchange, and the China Securities Regulatory Commission requires clarification on the specific details of the business involving large-scale AI models.

New stock news: Shanghai Jingzhi plans to go public in Hong Kong. The China Securities Regulatory Commission requires an explanation of the related stock option incentive plan and relevant circumstances.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


